All In Biotech

Drug Trial Radar · NCT06013423

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Jul 23, 2024

Primary completion

Oct 31, 2031

Study completion Oct 31, 2032

Sponsor

Lead sponsor
Fred Hutchinson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cord Blood Network
First posted
Aug 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before a donor cord blood transplant (CBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening in patients with high-risk hematologic diseases.

Conditions

  • Acute Leukemia of Ambiguous Lineage
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Hematopoietic and Lymphatic System Neoplasm
  • Mixed Phenotype Acute Leukemia
  • Myelodysplastic Syndrome
  • Myeloproliferative Neoplasm
  • Non-Hodgkin Lymphoma
  • Chronic Myeloid Leukemia, BCR-ABL1 Positive

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirateProcedure

    Undergo bone marrow aspirate

  • CyclophosphamideDrug

    Given IV

  • CyclosporineDrug

    Given IV or PO

  • Diagnostic Imaging TestingProcedure

    Undergo diagnostic imaging

  • Echocardiography TestProcedure

    Undergo ECHO

  • Fludarabine PhosphateDrug

    Given IV

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Mycophenolate MofetilDrug

    Given IV

  • Survey AdministrationOther

    Ancillary studies

  • ThiotepaDrug

    Given IV

  • Total-Body IrradiationRadiation

    Undergo high-dose or middle-intensity TBI

  • Umbilical Cord Blood TransplantationProcedure

    Undergo UCBT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: At 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.